BioPharma APAC

Contract Services Contract Manufacturing

Biogen to acquire full ownership of Samsung Bioepis

Agreement with Biogen to buyout Biogen's (50% -1 share) stake in Samsung Bioepis Joint Venture for up to USD $2.3 billion Transaction projected to ...

January 28, 2022 | News

GenScript ProBio initiates a CDMO Contract For Next-Generation CD47 Antibody with InnoBation Bio

InnoBation Bio, led by Seung-gu Kim (CEO), is a biopharmaceutical company specializing in the development of biomarkers, Chimeric Antigen Receptor (CAR) T ...

January 26, 2022 | News

Samsung Biologics Reports Fourth Quarter & Fiscal Year 2021 Financial Results

Q4'21 revenue of KRW 444.3 billion increased 18% compared to Q4'20. Q4'21 operating profit of KRW 128.8 billion increased 39% compar...

January 25, 2022 | News

WuXi STA Launches its First Parenteral Formulation Manufacturing Line

The industry-leading automatic parenteral filling line features multiple filling modules and a built-in lyophilizer to fill vials, syringes, and ...

January 24, 2022 | News

GenScript ProBio to Expand Commercial cGMP Plasmid and Viral Vector

On January 19, 2022, GenScript ProBio broke ground for the construction of its newest plasmid and viral vector manufacturing facility, a 34,000-square...

January 21, 2022 | News

Vetter's new clinical manufacturing site now officially authorized

Important milestone reached for the new site Additional filling capacities for early-stage clinical development First customer audits already completed...

January 20, 2022 | News

WuXi Biologics completes the first GMP inspection in 2022

WuXi Biologics a global company with leading open-access biologics technology platforms, announced that it has completed a remote GMP inspection by&n...

January 18, 2022 | News

Piramal Pharma Solutions Strengthens North American Capabilities

The Pharma Solutions (PPS) division of Piramal Enterprises Limited, a leading research, development and contract manufacturing (CDMO) organization, today...

January 14, 2022 | News

Samsung Biologics Shares Strategic Roadmap for Sustainable Growth

During the main track presentation today, John Rim, President and CEO of Samsung Biologics, addressed the company's vision for 2022 and business goals...

January 13, 2022 | News

Definitive Agreement to Acquire Exelead will Strengthen Merck’s CDMO Offering for mRNA

Merck, a leading science and technology company, has signed a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufac...

January 07, 2022 | News

WuXi Biologics, ImmuneOncia Sign MOU for Development and Manufacturing of Anti-PD-L1/CD47 Bispecific Antibody

Within the partnership, ImmuneOncia will have access to WuXi Biologics' integrated services in cell line development, cell culture development, biologics m...

December 28, 2021 | News

Curia Unveils Comprehensive mRNA Solution

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today unveiled its messenger RNA (mRNA) solution, which incl...

December 27, 2021 | News

Curocell, Breaks Ground on 'CAR-T Manufacturing GMP Facility'

The GMP Facility for commercial manufacturing CAR-T Cell therapy and R&D Center for further pipeline development are constituting the 17,325 square-met...

December 24, 2021 | News

Samsung Biologics adds to global ISO certifications with Quality Management System

Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, held an award ceremony with the British Standa...

December 08, 2021 | News

Stay Connected